Rafael Fonseca

Q: What Schools Are Affiliated With Rafael Fonseca

Rafael Fonseca is affiliated with the following schools: Emory University, City College of New York, University of Minnesota, Princeton University, Stanford University, University of Medicine and Dentistry of New Jersey, University of Toronto, University of Virginia, Rowan University, University of Manchester, University of Pennsylvania, Harvard University

Rafael Fonseca's AcademicInfluence.com Rankings

Rafael Fonseca

Computer Science

#3473

World Rank

#3645

Historical Rank

Computational Linguistics

#182

World Rank

#186

Historical Rank

Machine Learning

#415

World Rank

#421

Historical Rank

Artificial Intelligence

#612

World Rank

#623

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Why Is Rafael Fonseca Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Rafael Fonseca's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group (2003) (2143)
Review of 1027 patients with newly diagnosed multiple myeloma. (2003) (2065)
Initial genome sequencing and analysis of multiple myeloma (2011) (1385)
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. (2007) (1032)
Institutional change and healthcare organizations: from professional dominance to managed care (2002) (925)
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. (2010) (879)
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. (2006) (868)
Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. (2003) (834)
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review (2009) (813)
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. (2004) (748)
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. (2007) (733)
POEMS syndrome: definitions and long-term outcome. (2003) (695)
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. (2005) (649)
Clinical and biologic implications of recurrent genomic aberrations in myeloma. (2003) (625)
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. (2009) (609)
Clonal competition with alternating dominance in multiple myeloma. (2012) (595)
Genetics and Cytogenetics of Multiple Myeloma (2004) (566)
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. (2002) (535)
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. (2011) (525)
Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. (2005) (499)
IMWG consensus on risk stratification in multiple myeloma (2014) (473)
Prognostic value of bone marrow angiogenesis in multiple myeloma. (2000) (378)
Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. (2012) (373)
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. (2008) (365)
Cyclophosphamide, bortezomib and dexamethasone (CyBorD) induction for newly diagnosed multiple myeloma: High response rates in a phase II clinical trial (2009) (357)
Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. (2005) (349)
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. (2013) (344)
AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. (2008) (332)
Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma (2007) (328)
Genomic abnormalities in monoclonal gammopathy of undetermined significance. (2002) (325)
Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. (2012) (323)
Clinical course of patients with relapsed multiple myeloma. (2004) (321)
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. (2011) (313)
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. (2009) (309)
Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. (2002) (305)
Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. (2004) (303)
Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma (2014) (295)
Genetic aberrations and survival in plasma cell leukemia (2008) (295)
Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. (2002) (291)
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group (2013) (289)
The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. (2003) (286)
Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study (2010) (282)
Professional dynamics and the changing nature of medical work. (1995) (277)
The Social Construction of Reality: A Treatise in the Sociology of Knowledge. By Peter L. Berger and Thomas Luckmann. New York: Doubleday, 1966. Pp. 199. $5.95 (1967) (273)
Trends in overall survival and costs of multiple myeloma, 2000–2014 (2016) (244)
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. (2006) (235)
Clinical and Biological Implications of MYC Activation: A common difference between MGUS and newly diagnosed multiple myeloma (2011) (233)
Uncertainty and control in professional training. (1979) (232)
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. (2010) (229)
Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma (2003) (227)
Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. (2007) (226)
Thalidomide as initial therapy for early-stage myeloma (2003) (224)
Pharmaceutical research and development: what do we get for all that money? (2012) (224)
Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. (2012) (221)
Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. (2004) (215)
Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis. (2005) (213)
Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). (2003) (212)
Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. (2010) (212)
Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma (2006) (200)
Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. (2012) (200)
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy (2007) (199)
Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. (2008) (198)
Demythologizing the high costs of pharmaceutical research (2011) (194)
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM) (2010) (193)
Initial immunoglobulin M ‘flare’ after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia (2004) (190)
Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. (2010) (188)
Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study. (2002) (186)
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. (2007) (186)
Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. (2014) (185)
Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma (2013) (182)
Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. (2006) (181)
Thalidomide for previously untreated indolent or smoldering multiple myeloma (2001) (180)
Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. (2015) (179)
Follicular dendritic cell sarcoma and interdigitating reticulum cell sarcoma: A review (1998) (177)
Waldenström macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. (2002) (174)
Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project (2013) (172)
Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma (1999) (163)
Uncertainty and Professional Work: Perceptions of Physicians in Clinical Practice (1992) (158)
Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas (2015) (157)
Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. (2008) (156)
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. (2007) (155)
Expression of VEGF and its receptors by myeloma cells (2003) (152)
Identification of genes modulated in multiple myeloma using genetically identical twin samples. (2004) (151)
Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): A trial coordinated by the Eastern Cooperative Oncology Group (2007) (150)
Genetics and Cytogenetics of Multiple Myeloma: A Workshop Report (2004) (149)
Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma (2018) (148)
Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. (2001) (148)
Clinical and biological significance of RAS mutations in multiple myeloma (2008) (147)
Institutional Corruption of Pharmaceuticals and the Myth of Safe and Effective Drugs (2013) (146)
Introduction: The Structure of the Academic Professions (1974) (143)
Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia. (2009) (141)
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. (2009) (141)
Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis (2003) (139)
Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. (2012) (138)
Clinical significance of TP53 mutation in myeloma (2007) (137)
Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy (2001) (134)
Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. (2003) (133)
NHS plc: The Privatisation of Our Health Care (2006) (132)
Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations (2006) (128)
Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis. (2001) (127)
Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. (2005) (127)
Prognostic model for disease‐specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia (2006) (126)
Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. (2005) (126)
Promiscuous Rearrangements of the MYC Locus Hijack Enhancers and Super-Enhancers to Dysregulate MYC Expression in Multiple Myeloma (2014) (125)
Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. (2004) (123)
Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma. (2004) (123)
Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma (2008) (123)
Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. (2020) (123)
IAP antagonists induce anti-tumor immunity in multiple myeloma (2016) (120)
A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group. (2006) (118)
The practice and ethics of risk-rated health insurance. (1992) (118)
Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. (2012) (117)
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. (2010) (116)
Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus. (2002) (114)
The (11;14)(q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study. (2000) (113)
Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. (2018) (112)
The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition. (2008) (108)
A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. (2005) (107)
Monoclonal gammopathy of undetermined significance: a consensus statement (2010) (107)
Therapy for Relapsed Multiple Myeloma: GUIDELINES FROM THE MAYO STRATIFICATION FOR MYELOMA AND RISK‐ADAPTED THERAPY (2017) (107)
High cancer drug prices in the United States: reasons and proposed solutions. (2014) (106)
Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6. (2010) (106)
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. (2016) (104)
From managed competition to managed cooperation: theory and lessons from the British experience. (1997) (104)
Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. (2005) (104)
Commercial influence and the content of medical journals (2006) (102)
Prognostic value of angiogenesis in solitary bone plasmacytoma. (2003) (101)
Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016 (2017) (101)
Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. (1999) (101)
Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement. (2015) (100)
6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis (2007) (99)
Life on the edge: immigrants confront the American health system (2012) (98)
Waldenström macroglobulinaemia (2007) (97)
Pomalidomide (CC4047) Plus Low Dose Dexamethasone (Pom/dex) Is Active and Well Tolerated in Lenalidomide Refractory Multiple Myeloma (MM). (2009) (95)
Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma (2004) (95)
The clinical significance of cereblon expression in multiple myeloma. (2014) (94)
Clinical implication of centrosome amplification in plasma cell neoplasm. (2006) (92)
6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance. (2006) (92)
The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance. (2001) (91)
Safety at the Time of the COVID-19 Pandemic: How to Keep our Oncology Patients and Healthcare Workers Safe. (2020) (91)
MYC dysregulation in the progression of multiple myeloma (2019) (89)
High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy (2004) (87)
Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis (2009) (87)
Managed competition, governmentality and institutional response in the United Kingdom. (2001) (87)
Multiple myeloma and the translocation t(11;14)(q13;q32): a report on 13 cases (1998) (86)
The Inverse Benefit Law: How Drug Marketing Undermines Patient Safety and Public Health (2011) (84)
Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma. (2015) (81)
Primary plasma cell leukemia: Report of 17 new cases treated with autologous or allogeneic stem‐cell transplantation and review of the literature (2005) (80)
Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients (2000) (78)
Extraordinary claims require extraordinary evidence. (2005) (78)
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. (2021) (78)
Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. (2007) (77)
Randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (E4A03), a trial coordinated by the Eastern Cooperative Oncology Group: Analysis of response, survival, and outcome wi (2008) (76)
Targeting TMPRSS2 in SARS-CoV-2 Infection (2020) (76)
Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement (2018) (75)
Smoldering multiple myeloma requiring treatment: time for a new definition? (2013) (74)
The Road to Nowhere: The Genesis of President Clinton's Plan for Health Security (1997) (74)
Genome-Wide Characterization of Pancreatic Adenocarcinoma Patients Using Next Generation Sequencing (2012) (74)
Farnesyltransferase inhibitor FTI‐R115777 is well tolerat ed, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma (2003) (73)
Waldenström's macroglobulinemia. (2000) (73)
p53 haploinsufficiency and functional abnormalities in multiple myeloma (2014) (70)
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. (2014) (70)
Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy (2004) (70)
Long‐term results of the treatment of patients with mantle cell lymphoma with cladribine (2‐CDA) alone (95‐80‐53) or 2‐CDA and rituximab (N0189) in the North Central Cancer Treatment Group (2008) (69)
Treatment with bortezomib of a patient having hyper IgG4 disease. (2010) (68)
Making the NHS more like Kaiser Permanente (2004) (68)
Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma (2013) (66)
Methods for estimation of bone marrow plasma cell involvement in myeloma: Predictive value for response and survival in patients undergoing autologous stem cell transplantation (2001) (66)
Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib (2015) (66)
Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial (2011) (65)
IGF-1R is overexpressed in poor-prognostic subtypes of multiple myeloma (2006) (65)
Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. (2003) (65)
Carfilzomib and the cardiorenal system in myeloma: an endothelial effect? (2016) (64)
Professionalism as a countervailing power. (1991) (64)
Corporate medicine for profit. (1986) (64)
Foreign free riders and the high price of US medicines (2005) (64)
Effect of complete response on outcome following autologous stem cell transplantation for myeloma (2000) (63)
Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2. (2008) (62)
Autologous stem cell transplantation for relapsed and primary refractory myeloma (1999) (62)
Bone marrow angiogenesis in multiple myeloma: effect of therapy (2002) (62)
The risks of prescription drugs (2010) (62)
Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis. (2005) (61)
Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma. (1999) (61)
Leukocyte cell-derived chemotaxin 2 (LECT2)-associated amyloidosis is a frequent cause of hepatic amyloidosis in the United States. (2014) (61)
DNA methylation analysis determines the high frequency of genic hypomethylation and low frequency of hypermethylation events in plasma cell tumors. (2010) (60)
Implementing individualized medicine into the medical practice (2014) (60)
Introduction: A sociological perspective on rationing: power, rhetoric and situated practices (2001) (60)
Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity. (2008) (60)
The Sociological Character of Health-Care Markets (2000) (59)
Toward a new sociology of medical education. (1988) (59)
Proteomic analysis of waldenstrom macroglobulinemia. (2007) (58)
Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities (2012) (58)
Lessons from next-generation sequencing analysis in hematological malignancies (2013) (58)
Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma (2004) (58)
Benchmarks of Fairness for Health Care Reform (1996) (57)
Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach. (2013) (56)
Chromosomal abnormalities in systemic amyloidosis (1998) (56)
Comparative institutional response to economic policy managed competition and governmentality. (2001) (56)
Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie. (2010) (55)
Deletions of 17p13.1 and 13q14 are uncommon in Waldenström macroglobulinemia clonal cells and mostly seen at the time of disease progression. (2002) (54)
A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma (2012) (54)
Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma (1999) (54)
Clarithromycin (Biaxin)‐lenalidomide‐low‐dose dexamethasone (BiRd) versus lenalidomide‐low‐dose dexamethasone (Rd) for newly diagnosed myeloma (2010) (53)
Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia. (2015) (52)
Cerebral toxicity in patients treated for small cell carcinoma of the lung. (1999) (51)
Establishment and characterization of a novel Waldenstrom macroglobulinemia cell line, MWCL-1. (2011) (51)
Primary Central Nervous System Lymphomas: A Validation Study of Array-Based Comparative Genomic Hybridization in Formalin-Fixed Paraffin-Embedded Tumor Specimens (2011) (51)
Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma (2013) (51)
Universal health care: lessons from the British experience. (2003) (51)
Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma (2020) (50)
From migrant enclaves to mainstream: Reconceptualizing informal economic behavior (2004) (50)
Prognostic factors and staging in multiple myeloma. (2007) (50)
Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients (2016) (49)
Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma (2015) (49)
Monoclonal B-cell lymphocytosis is characterized by mutations in CLL putative driver genes and clonal heterogeneity many years before disease progression (2014) (49)
Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M3P) (2015) (48)
A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma (2005) (48)
Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-points. (2006) (47)
Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma (2010) (47)
Primary therapy with single agent bortezomib as induction, maintenance, and re-Induction in patients with high risk myeloma: results of the ECOG E2A02 trial (2010) (47)
Gene expression profiling of pulmonary mucosa-associated lymphoid tissue lymphoma identifies new biologic insights with potential diagnostic and therapeutic applications. (2009) (47)
Becoming psychiatrists: The professional transformation of self (1982) (46)
Manufacturing costs of HPV vaccines for developing countries. (2016) (46)
Identification of recurrent truncated DDX3X mutations in chronic lymphocytic leukaemia (2015) (46)
Estimated research and development costs of rotavirus vaccines. (2009) (45)
Ironies of success: a new history of the American health care "system". (2004) (45)
Targeted sequencing using a 47 gene multiple myeloma mutation panel (M3P) in ‐17p high risk disease (2015) (45)
Tumor-associated macrophages and extracellular matrix metalloproteinase inducer in prognosis of multiple myeloma (2016) (44)
Lenalidomide Plus Dexamethasone (Rev/Dex) in Newly Diagnosed Myeloma: Response to Therapy, Time to Progression, and Survival. (2006) (44)
Content development for the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM): use of qualitative and quantitative methods for scale construction. (2012) (44)
Psychiatry and Suicide: The Management of a Mistake (1972) (44)
Thrombosis in multiple myeloma (MM) (2012) (43)
The rhetorics and realities of community health care: the limits of countervailing powers to meet the health care needs of the twenty-first century. (1997) (43)
Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. (2011) (42)
Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma (2010) (42)
Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Myeloma: Long Term Follow up and Factors Predicing Outcome in 345 Patients (2012) (42)
Genomic Characterization of High-Count MBL Cases Indicates that Early Detection of Driver Mutations and Subclonal Expansion are Predictors of Adverse Clinical Outcome (2016) (42)
A phase II trial of imatinib in patients with refractory/relapsed myeloma (2006) (41)
An Integrated Genomic and Expression Analysis of 7q Deletion in Splenic Marginal Zone Lymphoma (2012) (41)
Longitudinal genome-wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse (2012) (41)
Why do cancer drugs get such an easy ride? (2015) (41)
The real ethics of rationing (1997) (41)
t(X;14)(p11;q32) in MALT lymphoma involving GPR34 reveals a role for GPR34 in tumor cell growth. (2012) (40)
Chromosome 1q21 abnormalities in multiple myeloma (2021) (40)
Molecular pathogenesis of Waldenström’s macroglobulinemia (2012) (39)
Global drug discovery: Europe is ahead. (2009) (39)
A Novel Measure of Chromosome Instability Can Account for Prognostic Difference in Multiple Myeloma (2013) (39)
Staging and prognostication of multiple myeloma (2014) (39)
Follicular dendritic cell sarcoma mimicking diffuse large cell lymphoma: A case report (1997) (38)
High-resolution genomic analysis in Waldenström's macroglobulinemia identifies disease-specific and common abnormalities with marginal zone lymphomas. (2009) (38)
Plasma levels of tumour necrosis factor alpha and interleukin‐6 predict progression‐free survival following thalidomide therapy in patients with previously untreated multiple myeloma (2003) (38)
Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy. (2010) (37)
Long‐term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma (2014) (37)
Homo Economicus : escaping the traps of managed competition (1995) (37)
Analysis of genetic abnormalities provides insights into genetic evolution of hyperdiploid myeloma (2006) (36)
Outcome with Lenalidomide Plus Dexamethasone Followed by Early Autologous Stem Cell Transplantation In the ECOG E4A03 Randomized Clinical Trial (2010) (35)
Beta2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma (1999) (35)
The U.S. Health System and Immigration: An Institutional Interpretation. (2009) (34)
Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis (2021) (34)
Multiple myeloma cells' capacity to decompose H2O2 determines lenalidomide sensitivity. (2017) (34)
Impact of high‐risk classification by FISH: an Eastern Cooperative Oncology Group (ECOG) study E4A03 (2011) (33)
Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study (2021) (33)
Downregulation of specific miRNAs in hyperdiploid multiple myeloma mimics the oncogenic effect of IgH translocations occurring in the non-hyperdiploid subtype (2013) (32)
Clinical significance of the translocation (11;14)(q13;q32) in multiple myeloma. (1999) (32)
Carfilzomib: A cause of drug associated thrombotic microangiopathy. (2016) (32)
Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature (2008) (32)
Life, death, and the insurance companies. (1994) (31)
The impact of medical school on future psychiatrists. (1975) (31)
The Impact of the Academic Revolution on Faculty Careers. (1973) (31)
Monoclonal Gammopathy of Undetermined Significance Does Not Affect Outcomes in Patients Undergoing Solid Organ Transplants (2011) (30)
Political values and health care : the German experience (1987) (30)
Thalidomide plus dexamethasone (thal/dex) and thalidomide alone (thal) as first line therapy for newly diagnosed myeloma (mm) (2000) (30)
Public-private relations in health care. (2001) (30)
Cytogenetic abnormalities in multiple myeloma. (1999) (29)
Comparison of twin and autologous transplants for multiple myeloma. (2008) (29)
Equity and efficiency in health care. (1992) (29)
Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma (MM): STORM Study (2016) (29)
Therapeutic options in patients with lymphoma and severe liver dysfunction. (2004) (28)
Institutional Change and Healthcare Organizations: From Professional Dominance to Managed Care. By W. Richard Scott, Martin Ruef, Peter J. Mendel, and Carol A. Caronna. Chicago: University of Chicago Press, 2000. Pp. xxv+426. $58.00 (cloth); $25.00 (paper). (2001) (28)
Plasma cell leukemia. (2011) (28)
Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial. (2005) (28)
Ploidy status rarely changes in myeloma patients at disease progression. (2006) (28)
Targeted therapeutics for multiple myeloma: The arrival of a risk-stratified approach (2007) (28)
Clinical Implementation of Integrated Genomic Profiling in Patients with Advanced Cancers (2016) (26)
Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma (2017) (26)
Sociological perspectives on competition in health care. (2000) (26)
Managed care: false and real solutions (1994) (26)
Venetoclax for the treatment of translocation (11;14) AL amyloidosis (2020) (26)
Historical and comparative reflections on the U.S. national health insurance reforms. (2011) (26)
Policy making on data exclusivity in the European Union: from industrial interests to legal realities. (2009) (26)
Is NHS purchasing serious? An American perspective (1998) (25)
Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma (2020) (25)
Analysis of Somatic Hypermutation and Antigenic Selection in the Clonal B Cell in Immunoglobulin Light Chain Amyloidosis (AL) (2004) (25)
Ductal Carcinoma in Situ of the Breast (1997) (25)
Natural history of thromboembolism in AL amyloidosis (2006) (25)
PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation (2016) (24)
Myeloma: classification and risk assessment. (2013) (24)
The development of professional schools in America (1982) (24)
Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients (2018) (24)
Effectiveness and efficiency under competition: the Cochrane test. (1991) (24)
Many and multiple myeloma(s) (2003) (23)
Training in ambiguity : learning through doing in a mental hospital (1980) (23)
Cereblon Expression Predicts Response, Progression Free and Overall Survival After Pomalidomide and Dexamethasone Therapy in Multiple Myeloma (2012) (23)
PKM2 and other key regulators of Warburg effect positively correlate with CD147 (EMMPRIN) gene expression and predict survival in multiple myeloma (2017) (23)
Phase II Trial of Lenalidomide (Revlimid™) with Cyclophosphamide and Dexamethasone (RCd) for Newly Diagnosed Myeloma (2008) (23)
Suicide Care: Obstacles in the Education of Psychiatric Residents (1976) (22)
Will Lower Drug Prices Jeopardize Drug Research? A Policy Fact Sheet (2004) (22)
Combination Therapy with CC-5013 (Lenalidomide; Revlimid™) Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma (MM). (2004) (22)
Genetics and cytogenetics of Waldenstrom's macroglobulinemia. (2003) (22)
DNA Methylation in Multiple Myeloma Is Weakly Associated with Gene Transcription (2012) (22)
Venetoclax For The Treatment of Translocation AL Amyloidosis (2019) (22)
High-Dose Chemotherapy with Early Autologous Stem Cell Transplantation Compared to Standard Dose Chemotherapy or Delayed Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis. (2018) (22)
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone (Pom/dex) Is Highly Effective Therapy in Relapsed Multiple Myeloma (2008) (22)
Hereditary Lysozyme Amyloidosis Variant p.Leu102Ser Associates with Unique Phenotype. (2017) (21)
Incidence of skeletal-related events among multiple myeloma patients in the United States at oncology clinics: Observations from real-world data (2018) (21)
Setting the record straight in the reply by DiMasi, Hansen and Grabowski (2005) (21)
1. Bearing the Risks of Prescription Drugs (2010) (21)
1. Bearing the Risks of Prescription Drugs (2010) (21)
Making Practical Markets for Vaccines (2005) (21)
Escaping the traps of postwar Western medicine How to maximize health and minimize expenses (1993) (21)
Observations on the NHS reforms: an American perspective. (1991) (21)
Good Managed Care Needs Universal Health Insurance (1999) (21)
High-throughput genomic analysis in Waldenström's macroglobulinemia. (2011) (20)
Categorical inequality, institutional ambivalence, and permanently failing institutions: the case of immigrants and barriers to health care in America (2012) (20)
Genetics of multiple myeloma. (2005) (19)
Genomic abnormalities of Waldenström macroglobulinemia and related low-grade B-cell lymphomas. (2013) (19)
Absence of tissue factor expression by neoplastic plasma cells in multiple myeloma (2012) (19)
MicroRNA expression in tumor cells from Waldenstrom's macroglobulinemia reflects both their normal and malignant cell counterparts (2011) (19)
Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma (2018) (18)
Embedded inefficiencies in health care (1991) (18)
Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution (2007) (18)
Review of molecular diagnostics in multiple myeloma (2007) (18)
Plasma cell leukemia (2001) (18)
Benchmarks of Fairness: A Moral Framework for Assessing Equity (1999) (18)
Social medicine vs professional dominance: the German experience. (1986) (18)
Whole Genome Analyses of a Well-Differentiated Liposarcoma Reveals Novel SYT1 and DDR2 Rearrangements (2014) (18)
Managed Care in a New Key: Britain's Strategies for the 1990s (1998) (18)
Clinical and pathological phenotype of leukocyte cell-derived chemotaxin-2 (LECT2) amyloidosis (ALECT2) (2010) (17)
Activity of 129 single-agent drugs in 228 phase I and II clinical trials in multiple myeloma. (2014) (17)
Misleading Congress about Drug Development (2007) (17)
Effect of Tissue Shipping on Plasma Cell Isolation, Viability, and RNA Integrity in the Context of a Centralized Good Laboratory Practice–Certified Tissue Banking Facility (2008) (17)
“Direct to Drug” screening as a precision medicine tool in multiple myeloma (2020) (17)
High Incidence of IgH Translocations in Monoclonal Gammopathies with Abnormal Free Light Chain Levels. (2006) (17)
Single Agent Bortezomib Is Associated with a High Response Rate in Patients with High Risk Myeloma. A Phase II Study from the Eastern Cooperative Oncology Group (E2A02). (2006) (17)
Erdheim Chester Disease treated successfully with cladribine (2016) (17)
Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. (2021) (17)
A phase ii trial of thalidomide in the treatment of relapsed multiple myeloma (mm) with laboratory correlative studies (2000) (16)
A novel report of cig‐FISH and cytogenetics in POEMS syndrome (2008) (16)
The costs of coronavirus vaccines and their pricing (2021) (16)
Centrosomes and myeloma; Aneuploidy and proliferation (2009) (16)
t(4;14)(p16.3;q32) is strongly associated with a shorter survival in myeloma patients (2003) (16)
The Sociological Calendar: An Analytic Tool for Fieldwork Applied to Medical and Psychiatric Training (1975) (15)
A simple additive staging system for newly diagnosed multiple myeloma (2022) (15)
Expression and mutation status of candidate kinases in multiple myeloma (2008) (15)
Strengthening the Theory of Institutional Corruptions: Broadening, Clarifying, and Measuring (2013) (14)
Globalizing Restricted and Segmented Markets: Challenges to Theory and Values in Economic Sociology (2007) (14)
Burden of disease progression in patients with multiple myeloma in the US (2020) (14)
Absence of tissue factor is characteristic of lymphoid malignancies of both T- and B-cell origin. (2014) (14)
Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up (2016) (14)
E1A06: A phase III trial comparing melphalan, prednisone, and thalidomide (MPT) versus melphalan, prednisone, and lenalidomide (MPR) in newly diagnosed multiple myeloma (MM). (2014) (14)
Extramedullary Cardiac Multiple Myeloma-A Case Report and Contemporary Review of the Literature. (2016) (14)
Kidney Transplant in the Era of Modern Therapy for Multiple Myeloma (2018) (14)
Disseminated Kaposi's sarcoma after heart transplantation: association with Kaposi's sarcoma-associated herpesvirus. (1998) (14)
Phase II Pilot Study of Rituximab + CHOP in Patients with Newly Diagnosed Waldenström’s Macroglobulinemia, an Eastren Cooperative Oncology Group Trial (Study E1A02). (2007) (14)
Cost Containment and the Backdraft of Competition Policies (2001) (14)
The ( 11 ; 14 ) ( q 13 ; q 32 ) Translocation in Multiple Myeloma A Morphologic and Immunohistochemical Study (2002) (13)
Impact of FISH and Cytogenetics On Overall and Event Free Survival in Myeloma: An IMWG Analysis of 9,897 Patients. (2009) (13)
Phase II Trial of Lenalidomide, Cyclophosphamide, and Dexamethasone (CRd) for Newly Diagnosed Myeloma. (2007) (13)
Strategies for risk-adapted therapy in myeloma. (2007) (13)
Review of the patient-centered communication landscape in multiple myeloma and other hematologic malignancies. (2019) (13)
Longitudinal Genome Wide Analysis of Patients with Chronic Lymphocytic Leukemia Reveals Complex Evolution of Clonal Architecture At Disease Progression and At the Time of Relapse (2011) (13)
Pomalidomide–dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial (2018) (13)
Consolidation therapy with bortezomib/lenalidomide/ dexamethasone versus bortezomib/dexamethasone after a dexamethasone-based induction regimen in patients with multiple myeloma: a randomized phase III trial. (2008) (13)
Effective Commissioning: Lessons from purchasing in American managed care (1998) (13)
Keeping competition fair for health insurance: how the Irish beat back risk-rated policies. (1998) (13)
Systolic dysfunction associated with carfilzomib use in patients with multiple myeloma (2017) (13)
Contributing to Scholarship and Theory through Public Sociology (2005) (13)
Lenalidomide Plus Low-Dose Dexamethasone (Ld): Superior One and Two Year Survival Regardless of Age Compared to Lenalidomide Plus High-Dose Dexamethasone (LD) (2010) (12)
Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of 225 Patients Treated in Five Cohorts Over Three Years, (2011) (12)
Genomics in multiple myeloma: biology and clinical implications. (2005) (12)
Values and structure in the German health care systems. (1985) (12)
Low Dose Single Agent Thalidomide Is Tolerated in Patients with Primary Systemic Amyloidosis, but Responses Are Limited. (2004) (12)
The FDA’s new clothes (2015) (12)
Introduction-Ironies of success: A new history of the American health care "system" (2005) (12)
Practical aspects in the diagnosis and management of aplastic anemia. (1997) (11)
A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR‐CD) for untreated low‐grade non‐Hodgkin lymphoma requiring therapy (2017) (11)
Genomics and proteomics in multiple myeloma and Waldenström macroglobulinemia (2007) (10)
FISH Demonstrates Treatment-Related Chromosome Damage in Myeloid but not Plasma Cells in Primary Systemic Amyloidosis (2000) (10)
The Combination of Cyclophosphamide-Bortezomib-Dexamethasone (CYBOR-D) Is a Highly Effective and Well Tolerated Regimen that Produces Rapid and Complete Hematological Response In Patients with AL Amyloidosis (2010) (10)
Thinking about Faculty. (1974) (10)
Barriers to out-of-hospital care for AIDS patients. (1994) (10)
Saving the pneumococcal AMC and GAVI (2011) (10)
PLASMA CELL LEUKEMIA : Consensus Statement on Diagnostic Requirements , Response Criteria , and Treatment Recommendations by the International Myeloma Working Group ( IMWG ) (2014) (10)
A Phase II Trial of Myeloma Induction Therapy with Cyclophosphamide, Bortezomib, and Dexamethasone (Cybor-D): Improved Response over Historical Lenalidomide-Dexamethasone Controls. (2007) (10)
Anti-Tumor Activity of Single-Agent CCI-779 for Relapsed Mantle Cell Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group. (2004) (10)
Efficacy of pomalidomide plus low-dose dexamethasone in multiple myeloma patients despite previous use of lenalidomide. (2011) (10)
Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen (2016) (10)
Introduction: Strengthening Ties Between Specialties and the Discipline (1992) (10)
Drug R&D Costs Questioned (2011) (10)
Superior Survival in Primary Systemic Amyloidosis Patients Undergoing Peripheral Blood Stem Cell Transplant : A Case Control Study Running Head: Survival in AL, Case Control Study (2004) (9)
Approach to a patient with cardiac amyloidosis (2019) (9)
Perestroika for Britain's NHS (1991) (9)
A Conservative Case for Universal Access to Health Care (2006) (9)
Is competition bad? (1983) (9)
The MYDas touch of next-gen sequencing. (2013) (9)
Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma. (2019) (9)
Efficacy of induction with cybord in newly diagnosed multiple myeloma (2008) (9)
Fostering a Justice-Based Health Care System (2000) (8)
Controlling Medical Professionals: The Comparative Politics of Health Governance (1991) (8)
Cytogenetic analysis using multiple myeloma targets in POEMS syndrome (2007) (8)
Global Pharmaceutical Markets (2010) (8)
Immunoglobulin Free Light Chain Ratio Is an Independent Risk Factor for Progression of Smoldering Multiple Myeloma. (2007) (8)
Dissecting karyotypic patterns in non-hyperdiploid multiple myeloma: an overview on the karyotypic evolution. (2013) (8)
Finding psychiatric diagnosis-related groups that work: a call for research. (1986) (8)
GERMANY'S HEALTH SYSTEM (1991) (8)
Thalidomide and dexamethasone in newly diagnosed multiple myeloma: Long-term results in patients not undergoing upfront autologous stem cell transplantation (2005) (8)
Pharmaceuticals as a market for "lemons": Theory and practice. (2020) (8)
The Ethics of Corporate Health Insurance (1991) (8)
MicroRNA Expression Analysis in Multiple Myeloma. (2005) (8)
A Phase-2 Study of Pomalidomide and Dexamethasone In Previously-Treated Light-Chain (AL) Amyloidosis (2010) (8)
Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature (2008) (8)
Phase 1/2 trial of ixazomib, cyclophosphamide, and dexamethasone for newly diagnosed multiple myeloma (NDMM). (2016) (8)
Dendritic cell-based idiotype vaccination for primary systemic amyloidosis (2000) (7)
Non-secretory myeloma: clinical and biologic implications. (2013) (7)
Expression and mutation status of candidate kinases in multiple myeloma (2007) (7)
Precision Medicine in Myeloma: Challenges in Defining an Actionable Approach (2017) (7)
A Pilot Program in Collaboration with African American Churches Successfully Increases Awareness of the Importance of Cancer Research and Participation in Cancer Translational Research Studies among African Americans (2012) (7)
Here we go again: repeating implementation errors (1999) (7)
A Pilot Study of Pomalidomide and Dexamethasone in Previously Treated Light Chain Amyloidosis Patients. (2009) (7)
Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation (2015) (7)
Reflections on commissioning and the English coalition government NHS reforms. (2011) (7)
Is G8 putting profits before the world's poorest children? (2007) (7)
Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Aspire (NCT01080391) (2015) (7)
The UK Health Care System (2018) (7)
Risk stratification of patients with newly diagnosed multiple myeloma: optimizing treatment based on pretreatment characteristics. (2005) (7)
The Patient Protection and Affordable Care Act: Is it good or bad for oncology? (2014) (6)
Treatment With Bortezomib‐based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective Study (2018) (6)
Detection of chromosome 13 deletions by fluorescent in situ hybridization. (2005) (6)
Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma. (2020) (6)
Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post‐autologous stem cell transplantation lenalidomide maintenance therapy (2021) (6)
Activation of TAK 1 by MYD 88 L 265 P drives malignant B-cell Growth in non-Hodgkin lymphoma (2014) (6)
Gene Expression Profiling of Myeloma Cells at Diagnosis Can Predict Response to Therapy with Thalidomide and Dexamethasone Combination. (2005) (6)
Treatment of Smoldering Multiple Myeloma: Expectant Observation Should Still Be the Standard. (2020) (6)
Laboratory correlates in multiple myeloma: how useful for prognosis? (2001) (6)
Phase II Study of Melphalan, Prednisone and Lenalidomide Combination for Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplantation (2008) (6)
A Phase I/II Trial Of Pomalidomide, Bortezomib and Dexamethasone In Patients With Relpased Or Refractory Multiple Myeloma (2013) (6)
The two tier syndrome behind waiting lists (2000) (6)
Professional Problems in Treating Suicidal Persons (1976) (6)
4. Pharmaceuticals and the Medicalization of Social Life (2010) (6)
Pharmaceutical Sales Representatives and Patient Safety (2013) (6)
A Phase II Study of PS-341 for Patients with High Risk, Newly Diagnosed Multiple Myeloma: A Trial of the Eastern Cooperative Oncology Group (E2A02). (2005) (6)
Alienation and Stress among Doctors: Dilemmas and Possible Solutions (2015) (6)
The Dynamics of University Protest (1977) (6)
Phase 1 Dose Escalation Study of the Monoclonal Antibody Against the Insulin Like Growth Factor I Receptor CP-751,871 in Patients with Multiple Myeloma. (2007) (5)
Phase II trial of nab‐paclitaxel in patients with relapsed or refractory multiple myeloma (2016) (5)
A Phase 2 Study Of Lenalidomide, Rituximab, Cyclophosphamide and Dexamethasone (LR-CD) For Untreated Low Grade Non-Hodgkin Lymphoma Requiring Therapy: Waldenström’s Macroglobulinemia Cohort Results (2013) (5)
Long Term Outcomes of Pomalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma: Analysis 4 Years After the Original Cohort (2011) (5)
Value and Cost of Myeloma Therapy-We Can Afford It. (2018) (5)
Spontaneous remission in a patient with t(4;14) translocation multiple myeloma. (2009) (5)
Regulation of drugs for early Alzheimer's disease. (2013) (5)
Risk factors for severe infection and mortality In patients with COVID‐19 in patients with multiple myeloma and AL amyloidosis (2022) (5)
Work Styles Among American Psychiatric Residents (1976) (5)
Phase II Trial Of Initial Safety and Toxicity Prior To The Phase III Trial Of Lenalidomide Versus Observation Alone In Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma (E3A06): A Trial Coordinated By The Eastern Cooperative Oncology Group (2012) (5)
Diagnosis and Staging of Multiple Myeloma and Related Disorders (2018) (5)
Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study (2022) (5)
Acute myocardial infarction: an unusual presentation of essential thrombocytosis in a 17-year-old man. (2008) (5)
Development of the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM) Scale and Validation in the Eastern Cooperative Oncology Group Trial E1A05, (2011) (5)
Promiscuous Mutations Frequently Activate the Non-Canonical NFkB Pathway in Multiple Myeloma (MM). (2006) (5)
Cyclophosphamide, Bortezomib and Dexamethasone (CYBORD) Treatment for Relapsed/Refractory Multiple Myeloma (2014) (5)
Genome-wide analysis reveals recurrent structural abnormalities of TP 63 and other p 53-related genes in peripheral T-cell lymphomas Running head : Genome-wide analysis of T-cell lymphomas (2012) (5)
In response: the ethics and value of professional medical writing assistance. (2013) (4)
Evidence for Cytogenetic and Fluorescence in Situ Hybridization (FISH) Risk Stratification of Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies. (2009) (4)
Prognosis in multiple myeloma. (1999) (4)
Loss of p53 Is a Marker of Progression in Plasma Cell Neoplasias and Is a Negative Prognostic Factor in Relapsed Disease. (2008) (4)
A Phase II Trial Comparison of Once Versus Twice Weekly Bortezomib in CYBORD Chemotherapy for Newly Diagnosed Myeloma: Identical High Response Rates and Less Toxicity. (2009) (4)
Phase I trial of chir-258 in multiple myeloma. (2006) (4)
Reversible Cardiotoxicity Associated with Carfilzomib Use in Patients with Multiple Myeloma (2016) (4)
Pomalidomide (CC4047) plus Low-Dose Dexamethasone (Pom/Dex) as Therapy for Relapsed Multiple Myeloma (2009) (4)
The t(4;14) Is Present in Patients with Early Stage Plasma Cell Proliferative Disorders Including MGUS and Smoldering Multiple Myeloma (SMM). (2005) (4)
Association of Clinical Researchers and Educators a statement on relationships between physicians and industry. (2012) (4)
Addressing Health Care Disparities: A Radical Perspective and Proposal (2020) (4)
The Radical Experiment: Transforming Britain's National Health System to Interlocking Markets (1992) (4)
Beyond The High Prices Of Prescription Drugs: A Framework To Assess Costs, Resource Allocation, And Public Funding. (2021) (4)
Practical Aspects in the Diagnosis and Management of Aplastic Anemia (1997) (4)
Reply to DiMasi, Hansen, and Grabowski (2008) (4)
The American Health System and Immigration: An Institutional Interpretation (2009) (4)
Clarithromycin (Biaxin)-Lenalidomide-Low-Dose Dexamethasone (BiRd) Versus Lenalidomide-Low-Dose Dexamethasone (Rd) as Initial Therapy for Newly Diagnosed Multiple Myeloma. (2009) (4)
Prediction of immunomodulatory drugs (IMiDs) sensitivity in myeloma via determination of baseline anti-oxidative stress capacity (2020) (4)
A comparison of lenalidomide/dexamethasone (RD) versus cyclophosphamide/lenalidomide/dexamethasone (CRD) versus cyclophosphamide/bortezomib/dexamethasone (CyborD) in newly diagnosed multiple myeloma (MM). (2010) (4)
Survival in Patients with Newly Diagnosed Myeloma Undergoing Therapy with Lenalidomide and Dexamethasone: Impact of High-Risk Cytogenetic Risk Status on Outcome (2008) (4)
The Importance of Economic Trade‐offs in Cancer Drug Pricing (2018) (4)
Transfusion-dependent anemia after initiation of androgen deprivation therapy for metastatic prostate cancer. (2007) (4)
Immigrant access in the Affordable Care Act: legacies of the Confederacy (2017) (4)
Social Participation in Public and Catholic Schools (1966) (4)
GO39775: A multicenter phase I trial evaluating the safety, pharmacokinetics, and activity of BFCR4350A, a FcRH5/CD3 T-cell dependent bispecific antibody, in patients with relapsed or refractory multiple myeloma. (2020) (4)
Costs and benefits of alcohol consumption (1975) (3)
Direct to Drug Screening As a Route to Individualized Therapy in Multiple Myeloma (2017) (3)
A Phase II Trial of Gleevec™ in Patients with Refractory/Relapsed Myeloma. (2004) (3)
Personalizing the Use of Circulating Microparticle-Associated Tissue Factor As a Biomarker for Recurrent Thrombosis in Patients With Cancer. (2017) (3)
Association of translocation t(11;14) with survival in patients with light chain (AL) amyloidosis (2008) (3)
Recurrent chromosome abnormalities define nonoverlapping unique subgroups of tumors in patients with chronic lymphocytic leukemia and known karyotypic abnormalities. (2013) (3)
The Cardiovascular Impact of Carfilzomib in Multiple Myeloma (2014) (3)
Frontline treatment of multiple myeloma (2012) (3)
Clinical Implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32) and -17p13 (p53) Deletions in Myeloma Patients Treated with High Dose Therapy. (2004) (3)
High Resolution Array-Based Analysis in Marginal Zone Lymphomas and Lymphoplasmacytic Lymphomas Identified Disease-Specific Patterns of Chromosome Abnormalities (2008) (3)
Characterization of Frontline Treatment Patterns and Attrition Rates According to Subsequent Lines of Therapy in Non-Transplant Patients with Newly Diagnosed Multiple Myeloma (2018) (3)
Corporate Physicians: Between Medicine and Management (1988) (3)
Should oncologists support the Affordable Care Act? (2013) (3)
Commentary: The New Paternalism (1999) (3)
On Motives and Moral Foundations for Our Work, Our Lives, Our Society (2008) (3)
Rationing : constructed realities and professional practices (2002) (3)
Survival outcomes in elderly patients with plasma cell myeloma: The three-decade Eastern Cooperative Oncology Group (ECOG) experience. (2011) (3)
Toward an Economic Sociology of Compassionate Charity and Care (2007) (3)
Management of multiple myeloma during COVID-19 pandemic (2020) (3)
Outpatients and their doctors: a study of patients, potential patients, general practitioners and hospital doctors by ? and ?. Department of Health, Institute for Social Studies in Medical Care, HMSO, London, 1992. £18.80. ISBN 0 11 321547 9 (1993) (3)
Feasibility and Impact of Digital Stories Intervention on Psychosocial Well-Being among Patients Undergoing Hematopoietic Cell Transplantation: A Pilot Study (2018) (3)
Betrayal by the surgeons (1996) (3)
[The new physician's role--quality, openness and confidence]. (2003) (3)
Do β2 microglobulin levels affect survival of newly diagnosed myeloma patients with translocation t(4;14) or 17p13 deletion treated with conventional chemotherapy? (2008) (3)
Impact of lenalidomide therapy on stem cell mobilization in myeloma (2008) (2)
Impact of IgVH Gene Mutational Status and VH Family Usage on Chromosomal Aberrations Detected by High-Resolution Array-CGH in B-CLL. (2009) (2)
Russia: Perestroika for health care? (1992) (2)
Erratum: Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature (Leukemia (2007) 10.1038/sj.leu.2404934) (2008) (2)
MYC Translocations Identified By Sequencing Panel in Smoldering Multiple Myeloma Strongly Predict for Rapid Progression to Multiple Myeloma (2017) (2)
Institutional Ambivalence and Permanently Failing Health Care: Access by Immigrants and the Categorically Unequal in the Nation and New Jersey (2009) (2)
How physicians interpret research funding disclosures. (2012) (2)
Genomic Variability in Multiple Myeloma (MM) Patients By Race: An Analysis of the Publically Available Mmrf Commpass Study Database (2016) (2)
Trump blames free riding foreign states for high US drug prices (2018) (2)
Promiscuous Cryptic Rearrangements of the MYC Locus Cis-Dysregulate MYC Expression and Are Present in the Majority of Patients with Hyperdiploid Myeloma (2012) (2)
Antibodies Create Killer Bonds in Myeloma. (2017) (2)
MALT lymphoma involving GPR 34 Reveals A Role for GPR 34 in Tumor Cell Growth (2012) (2)
CGH protocols: chronic lymphocytic leukemia. (2013) (2)
OAB-034: Evaluating the impact of cytogenetic abnormalities on treatment outcomes in patients with AL amyloidosis: subanalyses from the ANDROMEDA study (2021) (2)
Health Care Markets: Theory and Practice (2001) (2)
Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma (2022) (2)
Overexpression of the energy metabolism transcriptome within clonal plasma cells is associated with the pathogenesis and outcomes of patients with multiple myeloma (2022) (2)
PRL3 Is a Mediator of IL6/STAT3 Signaling and Defines a Population of Multiple Myeloma Patients Distinct from Those That Activate NFkB. (2007) (2)
Conflicts of interest, authorship, and disclosures in industry-related scientific publications. (2010) (2)
HOXA9 Is a Novel Therapeutic Target in Multiple Myeloma. (2009) (2)
Real-World Trends in Treatment Use, Healthcare Costs, and Overall Survival Among Patients with Multiple Myeloma (2016) (2)
What's so great about newness? (2007) (2)
Mapping the Sociology of Health and Medicine: America, Britain, and Australia Compared. By Fran Collyer. New York: Palgrave Macmillan, 2012. Pp. viii+325. (2013) (2)
Low Level Amplification (Duplication) of 1q21 in Myeloma and Prognosis; the Role of CKS1B. (2005) (2)
Use of the Serum Free Light Chain Assay in Assessment of Response to Therapy in Multiple Myeloma: Validation of Recently Proposed Response Criteria in a Prospective Clinical Trial of Lenalidomide Plus Dexamethasone for Newly Diagnosed Multiple Myeloma. (2005) (2)
Ineffectiveness of pulmonary irradiation in the treatment of leukemic blast crisis (1999) (2)
Connect MM: The multiple myeloma (MM) disease registry—Incidence of second primary malignancies (SPM). (2012) (2)
Longer exclusivity does not guarantee better drugs. (2011) (2)
OAB-052: Impact of chromosome 1 abnormalities on newly diagnosed multiple myeloma treated with proteasome inhibitor, immunomodulatory drug, and dexamethasone: analysis from the ENDURANCE ECOG-ACRIN E1A11 trial (2021) (2)
Comparison of Cytogenetics Between Asian and Caucasian Myeloma Reveal Higher Frequency of Abnormalities Associated with Poor Prognosis in Asian Patients (2011) (2)
Public health in the market: facing managed care, lean government, and health disparities (2002) (2)
Exaggerating the benefits of the 'decade of vaccines'. (2011) (2)
Multiple myeloma with t(11;14): unique biology and evolving landscape. (2022) (2)
Bone Disease in Myeloma: The Claws of CRAB (2016) (2)
Genome-Wide Analysis Uncovers Recurrent Alterations in Primary Central Nervous System Lymphomas (2012) (2)
Monoclonal antibody utilization characteristics in patients with multiple myeloma. (2017) (2)
GAVI's Advance Market Commitment (2010) (2)
Unraveling the multiple myeloma genome in the next-generation sequencing era: challenges to translating knowledge into the clinic (2011) (2)
Cell lines of hyperdiploid myeloma, are we there yet? (2008) (2)
Development and Results of a Multiple Myeloma Specific Custom 77-Gene Mutation Panel for Clinical Targeted Sequencing (2014) (2)
2. The Food and Drug Administration: Inadequate Protection from Serious Risks (2010) (2)
2. The Food and Drug Administration: Inadequate Protection from Serious Risks (2010) (2)
Innovation in myeloma treatments PARP excellence! (2011) (2)
Burden of Disease Progression in Patients with Multiple Myeloma Who Have Received at Least One Line of Therapy in the US (2018) (2)
A Phase 2 Study of Lenalidomide, Rituximab, Cyclophosphamide and Dexamethasone (LR-CD) for Untreated Low Grade Non-Hodgkin Lymphoma Requiring Therapy (2015) (2)
Will the NHS strategic plan benefit patients? (2008) (2)
Status, Purity, and Professional "Regression" (1984) (2)
The case of the phantom bladder. (1997) (2)
Pricing pharmaceutical drugs in the USA (2018) (2)
The SKY92 prognostic marker is validated in eight multiple myeloma clinical datasets (2016) (2)
Comprehensive Genomic Analysis of Metastatic Mucinous Urethral Adenocarcinoma Guides Precision Oncology Treatment: Targetable EGFR Amplification Leading to Successful Treatment With Erlotinib (2016) (2)
Racial Differences in Disease Characteristics: Understanding Multiple Myeloma in Hispanics (2017) (2)
Assays for neoplastic cell enrichment in bone marrow samples. (2003) (2)
Betrayal by the surgeons (1996) (1)
The development of novel targeted therapeutics for treatment of multiple myeloma research roundtable (2003) (1)
[Genetic markers as prognostic factors in multiple myeloma]. (2009) (1)
The Role of the Histone Demethyltransferase Gene JMJD1C and H3K9 Methylation in Multiple Myeloma (2012) (1)
Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma (2021) (1)
Combined High Resolution Array Comparative Genomic Hybridization and Gene Expression Profiling Reveal Rb1 Haploinsufficiency as a Possibile Tumorigenic Mechanism in Myeloma. (2006) (1)
“Direct to Drug” screening as a precision medicine tool in multiple myeloma (2020) (1)
A481 Long-Term Results of Single-Agent Thalidomide as Initial Therapy for Smoldering or Indolent Myeloma (2009) (1)
Prediction of response to bortezomib and dexamethasone resistance in myeloma (MM) by novel mutations in the NFKB pathway (2007) (1)
Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients (2023) (1)
A “not so micro” model for a “macro” problem (2005) (1)
Maintenance (MT) treatment (Tx) after lenalidomide, bortezomib, and dexamethasone (RVD) induction and stem cell transplant (SCT) in high-risk (HR) patients (pts) with newly diagnosed multiple myeloma (NDMM): A real-world analysis. (2018) (1)
Cytogenetic Abnormalities in Multiple Myeloma: The Importance of FISH and Cytogenetics (2008) (1)
GENOME-WIDE ANALYSIS UNCOVERS RECURRENT ALTERATIONS IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMAS (PCNSL) (2014) (1)
Up-Front Management of Multiple Myeloma (2010) (1)
Molecular classification of light chain (AL) amyloidosis by gene expression profiling (2004) (1)
Real-World Outcomes for Maintenance Treatment Sequencing after Receiving Lenalidomide, Bortezomib, and Dexamethasone Induction in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Followed By Autologous Stem Cell Transplant (ASCT) (2017) (1)
Molecular genetic aspects of plasma cell disorders (2013) (1)
Complementary Activation of Ccnd, MYC, RAS and NFkB By Mutations in Multiple Myeloma (2016) (1)
Superiority of Lenalidomide-Dexamethasone Versus Thalidomide-Dexamethasone as Initial Therapy for Newly Diagnosed Multiple Myeloma. (2009) (1)
The Genomic Landscape Of Primary Central Nervous System Lymphomas (2013) (1)
PARP Inhibition (OLAPARIB) Enhance Melphalan and Nutlin-3a Sensitivity in TP53 Positive Multiple Myeloma (2012) (1)
Abstract 4694: Indices of actionability and clinical utility in a CLIA-enabled study of whole genome/exome/RNA sequencing in 33 cancer patients: Actionable vs. utility (2014) (1)
Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Lenalidomide Refractory Myeloma: Long Term Follow up and Comparison of 2 Mg Vs 4 Mg Doses (2014) (1)
A Comprehensive Study of Chromosome 13 Abnormalities (Δ 13) in Multiple Myeloma Using High-Throughput, Array-Based Methods. (2004) (1)
Interim analysis of a phase II trial of nab-paclitaxel in patients with very advanced relapsed/refractory multiple myeloma (RR-MM). (2015) (1)
Treatment with Bortezomib (Bor) Based Therapy Followed By Autologous Stem Cell Transplantation (SCT) Improves Outcomes in Light Chain Amyloidosis (AL) (2016) (1)
Race- and health-related quality of life among patients newly diagnosed with multiple myeloma. (2012) (1)
Erratum: Expression and mutation status of candidate kinases in multiple myeloma (Leukemia (2007) vol. 21 (1124-1127) 10.1038/sj.leu.2404612) (2008) (1)
Analysis of Serial Patient Samples Reveals a Variety of Clonal Dynamics In Multiple Myeloma (2010) (1)
Deletion of 11q23 is a highly specific nonrandom secondary genetic abnormality of ETV6/RUNX1-rearranged childhood acute lymphoblastic leukemia (2007) (1)
Dysregulation of c-maf is associated with t(14,-16)(q32;q23) breakpoints that flank the FRA 16D fragile site within the WWOX gene, and can be greater than 1 MB from c-MAF (2000) (1)
Plasma Cell Folate Receptor Overexpression Differentiates Multiple Myeloma from Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma. (2004) (1)
TRAF3 and TNFAIP3, Two Negative Regulators of NF-Kb Signaling Pathways, Are Mutated in Waldenström’s Macroglobulinemia (2008) (1)
Multiple myeloma and FISH (but no CHIPS) (2007) (1)
A Gene Expression Based Centrosome Index Is a Powerful Prognostic Factor in Myeloma. (2006) (1)
Long-Term Results of Single-Agent Thalidomide as Initial Therapy for Asymptomatic (Smoldering or Indolent) Myeloma. (2006) (1)
Treatment of Multiple Myeloma and Related Disorders: DIAGNOSIS AND GENETIC CLASSIFICATION OF MULTIPLE MYELOMA (2008) (1)
Survival gains in multiple myeloma from 2003 to 2014. (2018) (1)
Eligibility f or H ematopoietic S tem-Cell T ransplantation for P rimary S ystemic A myloidosis I s a F avorable Prognostic F actor f or S urvival (2001) (1)
Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significance (2022) (1)
Kinome-Wide RNAi Studies in Human Multiple Myeloma Identify a Lymphoid Restricted Kinase GRK6 as a Selectively Vulnerable Target That Regulates STAT3/MCL1. (2009) (1)
Sequencing the Multiple Myeloma Kinome: Absence of Mutation in Known Malignancy-Associated Kinases. (2004) (1)
The “American (cancer) patients first” plan to reduce drug prices—A critical assessment (2018) (1)
14q32 Abnormalities and 13q Deletions Are Common in Primary Systemic Amyloidosis Using Cytoplasmic Immunoglobulin Fluorescence In Situ Hybridization (cIg-FISH). (2007) (1)
Comments on Nilson's “An Application of the Occupational ‘Uncertainty Principle’ to the Professions.” (1979) (1)
Is competition bad? (1983) (1)
The Clinical Experience: The Construction and Reconstruction of Medical Reality (Book). (1982) (1)
A Novel Measure of Chromosome Instability Is An Independent Prognostic Factor in Multiple Myeloma (2011) (1)
RB1 Haploinsufficiency Confers a Proliferation Advantage in Myeloma Cell Lines. (2007) (1)
PF643 CHARACTERIZATION OF FRONTLINE TREATMENT PATTERNS AND THE PROPORTION OF PATIENTS REACHING SUBSEQUENT LINES OF THERAPY IN TRANSPLANT ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (2019) (1)
Measuring Fairness: An Opportunity for Empirical Ethics (2004) (1)
Characterization of Atypical t(11;14) CCND1/IGH Translocations in Multiple Myeloma (2021) (1)
3. The Commercialization of Medical Decisions: Physicians and Patients at Risk (2010) (1)
Multiple Myeloma Patients and Risk of Skeletal Related Events - Real-World Evidence in US Oncology Clinics (2017) (1)
5. Medicalization and Risk Scares: The Case of Menopause and HRT (2010) (1)
Intermediate care. A new way through. (2000) (1)
Understanding sociology, student edition (1995) (1)
Variation in Health-Related Quality of Life (HRQOL) Among Multiple Myeloma Patients by Insurance Coverage (2011) (1)
A Newly Identified Translocation t(X;14)(p11;q32) In MALT Lymphoma Involving IGHS and GPR34 Reveals A Novel Role for GPR34 In Cell Growth and Tumor Development (2010) (1)
Germany's health care system (1991) (1)
Primary Health Care in the UK (2018) (1)
A Comparative Analysis of Chromosome 13 Gene Expression and Copy Number Changes in Multiple Myeloma Using Array-Based Methods. (2005) (1)
The Lack of Clinical Efficacy of Flavopiridol in Patients with Relapsed Refractory Myeloma. (2004) (1)
Use of genetic markers in multiple myeloma. (2017) (1)
Sick system. (2003) (1)
Managed Care Systems vs. Health Care Trends (1994) (1)
Diagnostic Evaluation of t[4;14] in Multiple Myeloma. (2006) (1)
Review of Richard Smith, The Trouble with Medical Journals (2007) (1)
Association of Race with Health-Related Quality of Life (HRQOL) Among Multiple Myeloma Patients (2011) (1)
Income Distribution: the First Stage in the Consideration of Poverty (1971) (1)
Managed competition: lessons from Britain. (1999) (1)
Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma (2022) (1)
The International War on Cheap Drugs (2004) (1)
Excluding more, covering less. The health insurance industry in the U.S. (1992) (1)
Response to Sol Yurick's "Political Economy of Junk"; Response to a Response (1971) (1)
Hidden or misreported trial results cause widespread patient harm (2013) (1)
Functional Assessment of Cancer Therapy--Multiple Myeloma Scale (2012) (1)
Good Science for Good Pharma—A Public-Health Model (2015) (1)
An Analysis of Erikson's and Piaget's Theories of Human Growth. Final Report. (1973) (1)
Activation of MYC Pathway Is a Unifying Pathological Event in the Progression from Monoclonal Gammopathy of Undetermined Significance (MGUS) to Myeloma (MM). (2007) (1)
Continuing medical education--limiting industry's influence. (2010) (1)
Diagnosis and Genetic Classifi cation of Multiple Myeloma (2008) (1)
6q Deletion in Waldenström Macroglobulinemia Is the Most Common Cytogenetic Abnormality and Is Associated with Aggressive Disease with a Trend towards Worse Survival. (2005) (1)
Association of High Levels of Free Light Chain and the Presence of Igh Translocations in Multiple Myeloma and Prognostic Implications. (2008) (0)
The PROMISE Study: A Nationwide Project for Predicting the Progression of Developing Myeloma in a High-Risk Screened Population (2019) (0)
Newly Diagnosed, Untreated, Multiple Myeloma (MM) Patient Samples Already Harbor Cereblon (CRBN) Exon 10 Deletions Associated with Drug Resistance (2022) (0)
amyloidosis rapid and complete hematologic response in patients with AL Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces (2012) (0)
Review of Renee C Fox's book, Doctors Without Borders (2015) (0)
Be Clear About Managed Care to Get Clear About Doctor-Patient Relations (2006) (0)
Toward understanding toxicity over time (ToxT) in myeloma cooperative group trials: Feasibility of a novel longitudinal adverse event analysis in ECOG-ACRIN E1A06. (2018) (0)
Patterns of Twitter use among trainees in hematology-oncology related areas. (2020) (0)
The Impact of the Central Carbon Energy Metabolism Transcriptome in the Pathogenesis and Outcomes of Multiple Myeloma (2021) (0)
BETRAYAL BY THE SURGEONS. AUTHOR'S REPLY (1996) (0)
Second symptomatic COVID-19 infections in patients with an underlying monoclonal gammopathy (2022) (0)
Pathogenic Germline Variants in a Prospective Multi-Center Cohort of Patients with Multiple Myeloma (2022) (0)
Multiple Myeloma (MM) Is Characterized by Genomic Instability Regardless of Ploidy Categories and Degree of Karyotypic Complexity Is an Important Prognostic Factor. (2007) (0)
The 1998 APHA Annual Lectu re What the UK can teach the US out health care (1999) (0)
Myeloma (mm) and the t(ll;14)(ql3;q32); increasing evidence for a biologically distinct subset of patients (2000) (0)
Immunomodulatory Drugs Inhibit H2O2 Decomposition in Multiple Myeloma Cells and Its Mediated Cytotoxicity Is Determined By Cellular Antioxidative Capacity (2015) (0)
Public Health Then andNow Social Medicine vsProfessional Dominance: TheGermanExperience (1986) (0)
Tissue Factor and Hematological Neoplasias (2012) (0)
Comprehensive High-Resolution Studies Differentiate and Characterize Hypodiploid Multiple Myeloma (2011) (0)
Talking to each other about universal health care: Do values belong in the discussion? reply (2006) (0)
Risk-Related Health Insurance-Reply (1993) (0)
Comparison of Multiple Myeloma Donor Patient Samples and Derived Cell Lines Identifies a Confirmed Hyperdiploid Myeloma Cell Line and Demonstrates Remarkable Genetic Similarity Between Cell Lines and Patient Samples (2008) (0)
Clinical and biological implication of defective p53 pathway in multiple myeloma (MM). (2006) (0)
Challenging Cases in Multiple Myeloma (0)
Identification of common and genetic subtype specific molecular programs associated with progression from monoclonal gammopathy of undetermined significance (MGUS) to myeloma (MM) (2007) (0)
Realistic ways to understand economic decisions: the sociologist’s perspective (2018) (0)
Improving medical practice and the economy through universal health insurance. (2005) (0)
Unique Characteristics and Outcomes of Therapy-Related Acute Lymphoblastic Leukemia (trALL) Following Therapy for Multiple Myeloma (MM) (2021) (0)
nonhyperdiploid dichotomy in MGUS A validated FISH trisomy index demonstrates the hyperdiploid and (2013) (0)
Pondering the U.S. health system. (1992) (0)
[Towards precision medicine in myeloma: new evidence and challenges]. (2017) (0)
Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma. (2023) (0)
Assessing Patient-Reported Financial Hardship in Patients With Cancer in Routine Clinical Care (2022) (0)
Analysis from the grassroots: how does pollution exposure vary by race and income? (2006) (0)
Murder in Academe (2011) (0)
GAVI-Human Vaccines-Article RESPONSE May 2011 (2013) (0)
Proteomic Analysis of Multiple Myeloma Identifies Potential Targets for Drug Therapy. (2004) (0)
Identification of Cellular Pathways Mediating Progression of Monoclonal Gammopathy (MGUS) to Multiple Myeloma (MM) Using Gene Expression Profiling (GEP). (2008) (0)
Causes of Death Among Patients with Multiple Myeloma: A 10 Year Longitudinal Analysis of a Population-Based Cohort in Ontario, Canada (2022) (0)
Gene Expression Profiling Identifies 4 Sub-Classes with Distinct Clinical Associations in Hyperdiploid Myeloma. (2005) (0)
Response to commentaries (2011) (0)
Establishment and Characterization of an Ig Lambda Secreting Cell Line from a Patient with AL Amyloidosis. (2006) (0)
Strategies for Risk-Adapted Therapy in Myeloma Multiple Myeloma (2007) (0)
What's so great about newness? Author's reply (2007) (0)
Generation of An Automated Tool for the Identification of Genetics Markers and Signatures in Multiple Myeloma Risk-Stratification (2011) (0)
Analysis of Intratumor Heterogeneity in Multiple Myeloma Using Methylcellulose Clonogenic Assays. (2004) (0)
Future challenges for hospitals and health care: an international perspective on the NHS 50th anniversary. (1999) (0)
Cancer Drugs, Costs and Benefits of (2015) (0)
Around the world in a month (2014) (0)
Moral Teachings from the Social Sciences (2000) (0)
early genetic events in patients with primary systemic amyloidosis Translocations involving the immunoglobulin heavy-chain locus are possible (2011) (0)
The Managed Care Blues and How to Cure Them, by Walter A. Zelman and Robert A. Berenson. Washington, D.C.: Georgetown University Press, 1998. 240 pp. (2000) (0)
Targeted sequencing of relapsed/refractory myeloma patients identifies an enrichment of mutations in MAPK and Cereblon pathways (2015) (0)
Dangerous DoseDeadly Medicines And Organised Crime: How Big Pharma Has Corrupted Healthcare By Gøtzsche Peter C. London (UK) : Radcliffe Publishing Ltd. , 2013 310 pp., $45.00 (2014) (0)
Search Results for: don\'t know what a vaccine adverse reaction is (2013) (0)
A simple additive staging system for newly diagnosed multiple myeloma (2022) (0)
Cooperative Oncology Group Study 13) in Multiple Myeloma : An Eastern Δ 13 Abnormalities ( Hybridization Detection of Chromosome in Situ Fluorescence and Prognostic Significance of Interphase (2013) (0)
Mutations in Driver Genes and Changes in Clonal Dynamics Are Associated with Shorter Time to Treatment in MBL Cases (2015) (0)
B581 MicroRNA Regulate Growth and Angiogenesis in Multiple Myeloma (2009) (0)
Abstract 4957: Comparison of commercial and custom microarrays: which is the best choice for copy-number analysis in tumor samples (2010) (0)
Combination T herapy W ith T halidomide P lus D examethasone for N ewly D iagnosed M yeloma (2002) (0)
Economic burden of disease progression among multiple myeloma patients who have received transplant and at least one line of therapy in the US (2021) (0)
Rationing: Constructed Realities and Professional Practices Developing Good Practice in Community Care (2002) (0)
A Single Next Generation Sequencing Assay for Detection of Driver Mutations, Translocations and Copy Number Alterations in Patients with Multiple Myeloma (2022) (0)
Proteomic Analysis of Waldenstrom Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM-MGUS) Identifies Potential Targets for Drug Therapy. (2004) (0)
Impact of Disease Progression, Line of Therapy, and Response on Health-Related Quality of Life in Multiple Myeloma: A Systematic Literature Review. (2022) (0)
College Youth: Psychohistory and Prospects (1975) (0)
Characterization of Waldenström Macroglobulinemia Subtypes using Global Gene Expression Profiling. (2004) (0)
Long-Term Survival With Cybord Induction Therapy In Newly Diagnosed Multiple Myeloma (2013) (0)
MicroRNA 15a and 16-1 Target Identification in Deletion 13 Multiple Myeloma (2008) (0)
and other p53-related genes in peripheral T-cell lymphomas TP63 Genome-wide analysis reveals recurrent structural abnormalities of (2012) (0)
Identification of Genes Associated with Increased Bone Marrow Angiogenesis in Multiple Myeloma. (2005) (0)
Rose, N. Our Psychiatric Future: the Politics of Mental Health. London: Polity. 2019. 269pp. (2019) (0)
The Health Impact Fund (2010) (0)
Evaluation of protocol mandated testing in E4A03, a randomized phase III study of CC-5013 plus dexamethasone versus CC-5013 plus low-dose dexamethasone in multiple myeloma (MM). (2013) (0)
Assessment of MRD in patients with hematologic malignancies: clinical insights. (2020) (0)
Gene Expression Profiling of Pulmonary Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma Identifies New Diagnostic Markers, Biological Heterogeneity and Therapeutic Targets. (2007) (0)
Educating the Public and Future Researchers (2015) (0)
Primary managed care. More choice, less cost. (1996) (0)
Reducing Global Health Inequality among Lower-income Girls: Making HPV vaccines Affordable (2014) (0)
Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) +/- Daratumumab Treatment Results in Sustained Hematologic Response in Patients with AL Amyloidosis: A Retrospective Analysis of Patients at Mayo Clinic (2022) (0)
Results of a Flow Cytometry Assay Measuring Oxidative Stress Relief As a Predictor of Immunomodulatory Drugs (IMIDs) Sensitivity in Myeloma (2018) (0)
The US Health Care System (2018) (0)
Sociology: functions of the family (1998) (0)
Medicine In The Thrall Of The Culture Of Drugs (2012) (0)
Evaluation of Revised International Staging System for Transplant-Eligible Multiple Myeloma Patients (2016) (0)
Tang, L. Recovery, Mental Health, and Inequality: Chinese Ethnic Minorities as Mental Health Service Users. Oxford: Routledge. 2017. 194 pp £105 (hbk) ISBN 9781138849976 (2018) (0)
Whole genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution and clonal tides Short title: Sequencing Reveals Natural History of Myeloma (2016) (0)
NCCTG phase H trial of 2-chlorodeoxyadenosbse (2-CDA) as therapy for previously treated mantle cell lymphoma: Promising single agent activity limited by brief response duration (2000) (0)
Genomc-Wide Profiling of Gene Expression and DNA Copy Number Alterations in Multiple Myeloma. (2007) (0)
Abstract 331: A comprehensive high-resolution genomic analysis of primary central nervous system lymphomas (PCNSL) shows a highly complex karyotype characterized by abnormalities affecting multiple genes involved in critical pathways associated with lymphocyte maturation and survival (2010) (0)
Genomic Strategies Determining Progression from MGUS to Multiple Myeloma (2013) (0)
Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Melphalan and Prednisone: A Case-Control Study in Newly Diagnosed Elderly Myeloma Patients. (2009) (0)
Identification of Survival Critical Genomic Gains or Losses in Myeloma (MM) Using Array-Comparative Genomic Hybridization (aCGH). (2007) (0)
The Organization of Medical Practice and the Practice of Medicine. (1987) (0)
Primary Health Care in the US (2018) (0)
Sociology@@@Readings and Review for Sociology (1977) (0)
Longitudinal Genomic Analyses In Chronic Lymphocytic Leukemia (CLL) Patients Reveal Clonal Relationship and Genomic Evolution In Disease Progression and After Therapy (2010) (0)
Generation of an automated tool for querying myeloma transcriptomics for multiple gene expression signatures used in risk-stratification. (2011) (0)
European Perspectives on Health Policy Issues (2012) (0)
Observations ontheNHSreforms: anAmerican perspective (1991) (0)
How physicians interpret research funding disclosures. (2012) (0)
Why Clinicians are Not Relying on Evidence from Indirect Comparison Studies Evaluating Comparative Efficacy of Interventions for Relapsed or Refractory Multiple Myeloma: A Critical Review: MM‐262 (2018) (0)
Cancer/Testis Antigen Profiling in Multiple Myeloma Define a Cohort of Patients with Poor Prognosis Regardless of Genetic Subtypes. (2005) (0)
Characterization of the Copy-Number Changes In Primary CNS Lymphomas (PCNSL) by High-Resolution Array-Based Comparative Genomic Hybridization (2010) (0)
Pondering The U.S. Health System (1992) (0)
Comparative High Resolution Array-Based CGH (aCGH) in B-Cell Malignancies. (2007) (0)
6232 8 D E C E M B E R 2 0 1 1 I V O L U M E 1 1 8 , N U M B E R 2 4 Blood (0)
Immunohistochemical Study of Tumor Associated-Macrophages and Microvessel Density in Multiple Myeloma (2022) (0)
Other side of British health reform. (1992) (0)
Psychiatry and Suicide: The Management (2016) (0)
Clinical actionability of measurable residual disease (MRD) assessment in the management of patients with hematologic malignancies: a case-based monograph. (2020) (0)
The FDA's new clothes The FDA does not protect patients from harmful or ineffective drugs, but approves both (2015) (0)
The effect of managed care on medical education. (2000) (0)
Intracellular Accumulation Of Light Chains Caused By Lenalidomide, and Mediated Via CRBN, Causes Major ER Stress and Is Implicated In The Synergistic Combination Of Imids and Proteasome Inhibitors (2013) (0)
Prevalence of BCL-2/J(H) Translocation in Healthy African Americans (2016) (0)
International Campaigns against Harmful Regulations and Practices (2015) (0)
Abstract 4243: Regulation of H3K9 methylation by the demethyltransferase gene JMJD1C in multiple myeloma. (2013) (0)
Role Of Folate Receptor Targeted Therapy In Multiple Myeloma (2013) (0)
Plasma Cells from Secondary Plasma Cell Leukemia Display Different Cytogenetics Pattern When Compared with Primary Plasma Cell Leukemia. (2005) (0)
The Changing Character of the Medical Profession: A Theoretical Overview (2019) (0)
Low-Risk Multiple Myeloma By SKY92+ISS Validated in the Multiple Myeloma Genomics Initiative Study (2015) (0)
Raising Consciousness (1977) (0)
Molecular Classification and Risk Stratification (2014) (0)
MM-361 The Prognostic Role and Utility of Highly Sensitive Minimal Residual Disease Assay in Multiple Myeloma: Is There Really a Difference? (2022) (0)
Abstract 5104: Identification of key tumorigenic pathways in pancreatic adenocarcinoma patients using massively parallel DNA and RNA sequencing (2012) (0)
Gene Expression Profiling of Hyperdiploid Multiple Reveal Complex Gene Dosage Effects and an mRNA Translation/Protein Synthesis Signature. (2005) (0)
Commentary--Sociological Perspectives on Competition in Health Care (2000) (0)
MYC Activation Is a Common Transformation Event in Myeloma and Associated with Poor Prognosis. (2009) (0)
PCN142 Association of Health-Related Quality of Life Among Patients With Multiple Myeloma With Insurance Coverage (2012) (0)
A conservative case for universal health insurance. (2005) (0)
Abstract 4822: Analysis of somatic copy number alterations associated with poor prognosis and progression of multiple myeloma in African Americans (2010) (0)
Characterization of free immunoglobulin light chains by mass spectrometry in light chain-associated amyloidosis (2001) (0)
Immunoglobulin light chain variable (V) region genes inﬂuence clinical presentation and outcome in light chain–associated amyloidosis (AL) chain–associated (2003) (0)
analysis of 411 patients dexamethasone in newly diagnosed multiple myeloma: a comparative Lenalidomide plus dexamethasone versus thalidomide plus (2013) (0)
Comparison of Newly Diagnosed and Relapsed Refractory Multiple Myeloma Using Transcriptional Profiling of Myeloma Cells. (2005) (0)
Ethics and the vaccine wars (2020) (0)
Economic evaluation of carfilzomib + lenalidomide + dexamethasone (KRd) vs. lenalidomide + dexamethasone (Rd) in relapsed or refractory multiple myeloma (R/RMM). (2016) (0)
report of the International Myeloma Workshop Consensus Panel 2 Consensus recommendations for risk stratification in multiple myeloma (2011) (0)
The Formative Years—Leadership, Culture, and Organization (2015) (0)
Health Care Systems: an International Overview (2018) (0)
From Measuring Environmental Toxins to Drugs as Contaminants (2015) (0)
Efforts to Undermine Public Heatlh The Inverse Benefit Law : How Drug Marketing Undermines Patient Safety and Public Health (2011) (0)
Plasma cell neoplasms (2010) (0)
Comprar Rationing: Constructed Realities and Professional Practices | DAVID HUGHES | 9780631228578 | Wiley (2008) (0)
The Multiple Myeloma Research Consortium Genomics Initiative. (2007) (0)
Abstract B64: Analysis of somatic copy number alterations among African American patients with multiple myeloma using array CGH (2010) (0)
Associations of DNA Repair Gene Polymorphisms in XRCC1 and ERCC2 with Clinical Outcome in ECOG Trial E9486. (2004) (0)
Origins and an American Vision for an Ethical, Independent Research Institute (2015) (0)
Functional Analysis of p53 in the JMW Myeloma Cell Line. (2005) (0)
Outcome with Lenalidomide Plus Dexamethasone Followed By Early Autologous Stem Cell Transplantation in the ECOG-ACRIN E4A03 Randomized Clinical Trial: Long-Term Follow-up (2015) (0)
PCN117 ASSOCIATION OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) WITH ISS STAGE AND ECOG STATUS IN MULTIPLE MYELOMA (2011) (0)
Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy (2022) (0)
Personal views: The two tier syndrome behind waiting lists (2000) (0)
Deletion 13 by FISH Provides Prognostic Information on Overall Survival and Time to Progression Independent of Serum Beta 2 Microglobulin and Bone Marrow Plasma Cell Labeling Index in Myeloma Patients Undergoing Stem Cell Transplantation. (2004) (0)
A Local Versus Centralized Processing Comparison of Plasma Cell Isolation, Viability, and RNA Integrity. (2005) (0)
Cancer esearch or and Stem Cell Biology Methylation Analysis Determines the High Frequency enic Hypomethylation and Low Frequency of R ermethylation Events in Plasma Cell Tumors (2010) (0)
Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma (2020) (0)
NHS culture depends on enlightened leadership and aligned incentives (2008) (0)
CpG Methylation Profiling in Multiple Myeloma. (2009) (0)
RISK-RELATED HEALTH INSURANCE. AUTHOR'S REPLY (1993) (0)
PRIMA-1 (p53 Reactivation and Induction of Massive Apoptosis) Mediates Anti-Myeloma Effect through the ER Stress Pathway (2014) (0)
High Resolution Array CGH Identifies TRAF3 as a Novel Tumor Suppressor in Multiple Myeloma. (2006) (0)
Deletions of 13ql4 in myeloma plasma cells usually represent large deletions of the q arm or monosomy (2000) (0)
Search Results for: merck (2013) (0)
B539 Proteomic Analysis of Multiple Myeloma Identifies Upregulation of the Novel Protein CRIK (2009) (0)
Cytogenetic Abnormalities in MGUS and Myeloma (2013) (0)
Response by the Writing Committee of the Association of Clinical Researchers and Educators (ACRE) (2013) (0)
Doctors Without Borders (2015) (0)
Problems and Prospects for Social Problem Texts@@@Social Problems.@@@Social Problems in American Society.@@@Confronting Social Problems.@@@Social Problems through Social Theory.@@@Urban Problems in Sociological Perspective.@@@Social Issues and the Social Order: The Contradictions of Capitalism.@@@So (1985) (0)
Interim Analyses of the MMRC Reference Collection Identifies Recurrent Genomic-Level Events in Multiple Myeloma and Demonstrates That CDKN2C/p18 Deletion Is the Pre-Eminent Copy Number Alteration in Poor Prognosis Disease (2008) (0)
High Risk Multiple Myeloma Cases Are Identified In An MMRC Led Study By The SKY92 Gene Signature (MMprofiler) (2013) (0)
Abstract 2021: Characterization of myeloma tumors from a multi-ethnic cohort using cytogenetics and genomic analysis. (2013) (0)
Pioneering Ethical Trials for Integrated Research (2015) (0)
Genomic Analysis of High Hyperdiploid Acute Lymphoblastic Leukemia and Hyperdiploid Multiple Myeloma Suggests Differential Gene Dosage Effect on Expression and Provide Clues to Preferential Selection of Recurrently Trisomic Chromosomes. (2005) (0)
Proteomic Analysis of Multiple Myeloma Identifies Upregulation of CRIK Protein, a Novel Protein Regulating Migration and Adhesion (2008) (0)
Amitriptyline-induced agranulocytosis with bone marrow confirmation. (2014) (0)
Science-Based Initiatives against Dangerous or Useless Drugs (2015) (0)
Acknowledgement to Referees (2018) (0)
Do Cytogenetics Predict Likelihood to Attain Minimal Residual Disease (MRD) Post Autologous Stem Cell Transplantation (SCT) in Multiple Myeloma (MM)? (2019) (0)
Medical Care Capsule Primary Managed Care: More Choice, Less Cost (1996) (0)
Cost Containment by a Naval Armada (1985) (0)
Identifying Mechanisms Associated with Venetoclax Resistance in Multiple Myeloma (MM) (2021) (0)
Loss of KDM6A/UTX Function Is a Common Event in a Mouse Model of Multiple Myeloma, Human Cell Lines and Patients. (2009) (0)
Acknowledgment of Reviewers 2021. (2021) (0)
Doctors Without Borders (2015) (0)
Author reply (2000) (0)
The green in between (2007) (0)
significance Genomic abnormalities in monoclonal gammopathy of undetermined (2013) (0)
One Half of Patients with Waldenström Macroglobulinemia Have Large Deletions of Chromosome 6q. (2005) (0)
Another look at rationing and technology. (1992) (0)
diagnostic and therapeutic applications tissue lymphoma identifies new biologic insights with potential Gene expression profiling of pulmonary mucosa-associated lymphoid (2008) (0)
Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma (2018) (0)
Ethnic&Racial Studies-Life on the Edge 2012 (2014) (0)
Risk Assessment and Stratification (2015) (0)
IgH translocations are common in patients with primary systemic amyloidosis (al) (2000) (0)
P-204: Carfilzomib, Dexamethasone, and Daratumumab (KdD) vs Kd: subgroup analysis of the CANDOR study by prior autologous stem cell transplantation, Lenalidomide exposure, or Lenalidomide refractory disease (2021) (0)
Mario Negri Institute: A public health model for developing new drugs (2014) (0)
Abstract 5064: Cytogenetic and somatic characterization of myeloma tumors from a multi-ethnic cohort (2012) (0)
The “Trans-Amplicon” in Myeloma; a Mechanism of Clonal Selection Favoring Retention of Derivative Chromosomes Involved in Translocations. (2005) (0)
amyloidosis Activity of pomalidomide in patients with immunoglobulin light-chain (2012) (0)
TheInverseBenefitLaw:HowDrugMarketingUnderminesPatient SafetyandPublicHealth (2011) (0)
Improving the Definition of Response Assessment: Prognostic Value of Minimal Residual Disease Combined with PET/CT at Day 100 Post Autologous Stem Cell Transplantation in Multiple Myeloma (2020) (0)
Expansions to New Campuses and Integrated Research (2015) (0)
Abstract B48: Similar prevalence of t(14,18) in African American and Caucasian subjects (2016) (0)
Why managed competition won't work revisited (1995) (0)
Ikaros expression levels to predict response and survival following pomalidomide and dexamethasone in multiple myeloma (MM). (2014) (0)
Proteomic Analysis of Targeted Therapeutic Agents in Multiple Myeloma (MM). (2004) (0)
JHE-Reply-1034-44 (2013) (0)
heavy chain locus translocations but have frequent 6q deletions Waldenström macroglobulinemia neoplastic cells lack immunoglobulin (2013) (0)
Impact of Treatment Sequencing on Overall Survival in Patients with Transplant-Ineligible Newly Diagnosed Myeloma. (2023) (0)
Genomic Landscape and Clonal Heterogeneity Underlying Progression and Relapse In Chronic Lymphocytic Leukemia (CLL) (2013) (0)
Patients with Monoclonal Gammopathy Have a High Rate of Second Symptomatic COVID-19 Infection Even after a Prior COVID-19 Infection and Vaccination (2022) (0)
Myeloma Cells Addicted to Glutamine for Biomass Production Are Sensitive to Lenalidomide (2019) (0)
Escaping the traps of postwar Western medicine* (2019) (0)
ECOG multiple myeloma (MM) clinical trial (CT) accrual performance evaluation utilizing the NCITrial Complexity and Elements Scoring (NCI-TCES) and the NCI Myeloma Steering Committee Accrual Working Group (NCI MYSC AWG) scoring models. (2014) (0)
Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma (2022) (0)
Economic Burden of Disease Progression Among Transplant Eligible Multiple Myeloma Patients Who Have Received at Least One Line of Therapy in the US (2019) (0)
Abstract 5081: Comprehensive genomic analysis of primary CNS lymphomas (PCNSL) identifies multiple dysregulated genes involved in immune response, regulation of apoptosis, lymphocyte maturation and activation (2012) (0)
Recurrent Chromosome Abnormalities Define Non-Overlapping, Unique Subgroups of Tumors in Chronic Lymphocytic Leukemia Patients with Known Karyotypic Abnormalities (2008) (0)
light-chain amyloidosis: long-term results from a phase 2 trial Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for (2012) (0)
Financial Hardship Amongst Patients with Hematologic Malignancies: Using the EMR to Streamline and Prioritize Patient-Centered Care (2021) (0)
Inactivation of Tumor Necrosis Factor 3 Gene (TRAF3) Is Frequently Identified in Waldenström’s Macroglobulinemia Patients. (2007) (0)
Cancer Rx: the $100,000 myth (2014) (0)
patients from the International Myeloma Working Group favorable features and shows better survival: an analysis of 10 549 Myeloma in patients younger than age 50 years presents with more (2008) (0)
Re: Response to Light/Lexchin Commentary (2017) (0)
Comparison of Myeloma Cell Gene Expression Profiles Pre and Post Thalidomide - Dexamethasone Therapy Provides Insight into Potential Mechanisms. (2005) (0)
Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma (2023) (0)
Role of Hepcidin In Anemia of Waldenström Macroglobulinemia (2010) (0)
Prognostic Value of Month 1 Bone Marrow and PET MRD Status in CAR-T Therapy for Myeloma (2022) (0)
Measles, rubella, and mumps titers post chemotherapy plus autologous stem cell transplant in multiple myeloma patients (2021) (0)
Managed care. (1997) (0)
The multi-institutional myeloma group clinico-genomic risk stratification system: A blinded validation. (2009) (0)
Lenalidomide Inhibits Thioredoxin Reductase (TrxR) in Multiple Myeloma (MM) Cells but Direct Inhibition of Trxr and Thioredoxin (Trx) Can Bypass Requirement of Cereblon (CRBN) (2016) (0)
Ornithine Decarboxylase: Novel Prognostic Marker and Target for Multiple Myeloma Therapy (2015) (0)
A Comprehensive High-Resolution Genomic Analysis of Primary Central Nervous System Lymphomas Shows a Highly Complex Karyotype Characterized by Abnormalities Affecting Multiple Genes Involved in Critical Pathways Associated with Lymphocyte Maturation and Survival. (2009) (0)
Epilogue: Toward Safer Prescribing and Better Drugs (2010) (0)
Deep sequencing identi fi es genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia (2014) (0)
unique molecular profile for light chain amyloidosis Functional gene expression analysis of clonal plasma cells identifies a (2013) (0)
Dysregulation of GPR34 in Indolent Lymphomas and Its Function As a Novel Regulator of Cell Growth and Gene Expression (2011) (0)
An Open-Label Phase 2 Study of Carfilzomib plus Dexamethasone to Assess Tolerability and Adherence in Patients with Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers (2018) (0)
Waldenström Macroglobulinaemia: The Impact of Cytogenetic Analysis. (2007) (0)
Clinical Significance of the Tumor Suppressor p53 Codon 72 Polymorphic Variants in Multiple Myeloma. (2005) (0)
Measles, Mumps & Rubella Titers Post Autologous Stem Cell Transplant in Multiple Myeloma Patients Induced with Modern Therapy (2020) (0)
Compendium of Karyotypic Abnormalities and Their Clinical Implications in Hyperdiploid Multiple Myeloma (H-MM). (2005) (0)
Myeloma with t(11;14) and CD20+ Plasma Cells: Response to Rituximab. (2005) (0)
High Density Oligonucleotide Array CGH Analysis of CLL Reveals Areas of Recurrent Genomic Gain or Loss. (2006) (0)
Activity of Single Agent Drugs in Phase I and II Trials Best Predicts Future Clinical Utility in Multiple Myeloma (2012) (0)
Epilogue: Toward Safer Prescribing and Better Drugs (2010) (0)
Books in review (1998) (0)
light chain-secreting human cell lines, ALMC-1 and ALMC-2 Biologic and genetic characterization of the novel amyloidogenic lambda (2013) (0)
Leveraging the electronic medical record (EMR) to predict patient reported financial hardship in cancer patients. (2021) (0)
Dissecting the Genetic Basis of Marginal Zone Lymphoma Reveals a Predilection for NF-Kb Activation by Clonal MZL Located at Extranodal Sites (2010) (0)
Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma (2019) (0)
non-hyperdiploid variant multiple myeloma The recurrent IgH translocations are highly associated with (2013) (0)
Impact of cytogenetic abnormalities on treatment outcomes in patients with amyloid light-chain amyloidosis: subanalyses from the ANDROMEDA study. (2023) (0)
Overt Multiple Myeloma Acquired Fanconi Syndrome Is an Indolent Disorder in the Absence of (2013) (0)
LP-118, a Novel BCL2 Inhibitor, Shows Potent in Vitro Anti-Myeloma Activity (2022) (0)
Genomic Complexity and Recurrent Aberration in Multiple Myeloma: Analysis of a Compendium of aCGH and Gene Expression Profiles. (2008) (0)
Abstract 3572: Copy number detection using genomics technologies: A comparison between aCGH and NGS (2014) (0)
Role of Fluorescence in Situ Hybridization in Myeloma Risk Stratification (2009) (0)
Plasma cell disorders (2019) (0)
Natural History, Genetic Aberrations and Survival Distinguish Primary Plasma Cell Leukemia from Multiple Myeloma with Leukemic Transformation. (2006) (0)
Daratumumab Plus Lenalidomide and Dexamethasone (DRd) Compared to Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Relapsed Lenalidomide-Exposed or Refractory Multiple Myeloma (MM) Patients: The Mayo Clinic Experience (2020) (0)
Abstract 219:TP53loss: An overriding marker of disease progression in Multiple Myeloma (2011) (0)
Multiple Myeloma (MM) in Young Patients (pts): Clinical Features and Outcome in 259 Patients Younger Than 40 Years in Comparison to 8,296 pts Aged ≥ 40 Years. (2005) (0)
Therapeutic Outcomes of Relapsed-Refractory Multiple Myeloma Patients with 1q21+Treated with Daratumumab-Based Regimens: A Retrospective Analysis (2022) (0)
Impact of high-risk classification by FISH on overall survival in myeloma: An Eastern Cooperative Oncology Group (ECOG) study E4A03. (2010) (0)
Systolic dysfunction associated with carfilzomib use in patients with multiple myeloma (2017) (0)
Dissecting Karyotypic Patterns in Non Hyperdiploid Multiple Myeloma: An Overview on the Karyotypic Evolution. (2007) (0)
Novel Associations Between Mutations, Prognostic and Clinical Parameters in Untreated Progressive CLL: Data from E1912, a Randomized Phase III Study of the ECOG-ACRIN Cancer Research Group (2016) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Rafael Fonseca?

Rafael Fonseca is affiliated with the following schools:

Rafael Fonseca's Academic­Influence.com Rankings

Why Is Rafael Fonseca Influential?

Rafael Fonseca's Published Works

Published Works

What Schools Are Affiliated With Rafael Fonseca?

Rafael Fonseca's AcademicInfluence.com Rankings